HC Wainwright Has Weak Outlook for Femasys FY2026 Earnings

Femasys Inc. (NASDAQ:FEMY) – Analysts at HC Wainwright lowered their FY2026 EPS estimates for Femasys in a note issued to investors on Wednesday, March 19th. HC Wainwright analyst E. Bodnar now anticipates that the company will post earnings per share of ($0.40) for the year, down from their prior estimate of ($0.39). HC Wainwright currently has a “Buy” rating and a $15.00 target price on the stock. The consensus estimate for Femasys’ current full-year earnings is ($0.86) per share. HC Wainwright also issued estimates for Femasys’ FY2027 earnings at ($0.31) EPS, FY2028 earnings at ($0.16) EPS and FY2029 earnings at $0.12 EPS.

Femasys Trading Up 2.6 %

NASDAQ FEMY opened at $1.60 on Monday. The company has a market capitalization of $36.64 million, a price-to-earnings ratio of -1.98 and a beta of -2.85. The company has a debt-to-equity ratio of 0.86, a current ratio of 3.94 and a quick ratio of 3.26. Femasys has a 12 month low of $0.86 and a 12 month high of $1.84. The company’s fifty day moving average price is $1.39 and its two-hundred day moving average price is $1.22.

Hedge Funds Weigh In On Femasys

Several large investors have recently modified their holdings of FEMY. Citadel Advisors LLC acquired a new stake in Femasys during the fourth quarter valued at approximately $45,000. Northern Trust Corp increased its holdings in shares of Femasys by 42.6% in the 4th quarter. Northern Trust Corp now owns 126,096 shares of the company’s stock valued at $139,000 after acquiring an additional 37,675 shares during the last quarter. Jane Street Group LLC acquired a new stake in shares of Femasys during the 4th quarter valued at approximately $30,000. Virtu Financial LLC bought a new position in Femasys during the fourth quarter worth $25,000. Finally, XTX Topco Ltd boosted its holdings in Femasys by 123.9% in the third quarter. XTX Topco Ltd now owns 32,535 shares of the company’s stock worth $36,000 after purchasing an additional 18,004 shares during the period. Institutional investors own 65.27% of the company’s stock.

About Femasys

Femasys Inc, a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.